Respiratory viruses
Baloxavir for influenza (CAPSTONE-1) and nirsevimab for RSV in infants (MELODY).
- Trials
- 2
- Years
- 2018–2022
Sort
- 2022MELODYRSV in infantsIn 1,490 healthy late-preterm and term infants, a single intramuscular dose of nirsevimab reduced medically attended RSV-associated lower-respiratory-tract infection compared with placebo.1.2% vs 5.0%Read →
- 2018CAPSTONE-1InfluenzaIn 1,436 outpatients aged 12–64 with uncomplicated influenza, a single dose of baloxavir shortened time to symptom alleviation compared with placebo with much faster viral-load decline.Read →